Management

Tarveda has built a team of innovative and successful drug developers whose deep collective experience spans drug discovery, research, and development at leading biotechnology and pharmaceutical companies.

Drew FromkinDrew Fromkin has nearly 30 years of leadership experience in major areas of the healthcare industry, including the biopharmaceuticals, life sciences and healthcare services sectors. He has an accomplished track record leading public and private companies through all stages of growth, including product development and commercial operations. Prior becoming the CEO of Tarveda Therapeutics, Mr. Fromkin served as President, CEO and Director of Clinical Data, Inc. (NASDAQ: CLDA) where he transformed the Company from a traditional diagnostics business with a sub-$100 million market capitalization to an innovative biopharmaceutical and personalized medicine company. Clinical Data was acquired for $1.2 billion by Forest Laboratories. Prior to Clinical Data, Mr. Fromkin served as President and CEO of DoctorQuality, Inc. (acquired by Quantros, Inc.), President, CEO and Director of Endo Surgical Devices, Inc. and Corporate Vice President, Business Development, for Merck-Medco, a wholly-owned subsidiary of Merck & Co. Mr. Fromkin began his career at Health Information Technologies, Inc. as General Manager of their subsidiary, MCA, and Director of Marketing and Payer Alliances for the parent company. He also recently served as a director and Chair of the compensation committee for Tobira Therapeutics, Inc. (TBRA), which has recently been acquired for $1.7 billion by Allergan (AGN). Mr. Fromkin was named to Business Week's "CEOs 40 and Under" list while at Clinical Data. Mr. Fromkin holds a B.A. from Brandeis University.

Leila Alland, M.D.

Brian Roberts joined Tarveda Therapeutics as Chief Financial Officer in January 2018. Brian has nearly 25 years of finance, capital markets and operations experience spanning the lifesciences, medtech and media industries with a proven track record of delivering positive results and driving shareholder value. Mr. Roberts served as Chief Financial and Operating Officer at Avedro, Inc., a privately held biotechnology company leading the organization through FDA approval, manufacturing readiness and commercial launch of its lead combination drug and medical device product. Previously, he served as Chief Financial Officer at Insulet Corporation, (NASDAQ: PODD) a leader in tubeless insulin pump technology. During his tenure, Insulet grew rapidly to nearly $300 million in revenue with a valuation of over $2 billion. Prior to Insulet, Brian served as CFO for Jingle Networks, acquired by Marchex, Inc., and as CFO for Digitas, (NASDAQ: DTAS) a leading digital marketing and media services firm acquired for $1.3 billion by Publicis Groupe. Brian has also held finance positions at Idiom Technologies, Inc., the Monitor Group and as an auditor with Ernst & Young LLP. Brian currently serves as Director and Audit Chairman for ViewRay, Inc., (NASDAQ:VRAY), a leader in MRI-guided radiation therapy, and as Director and Audit Chairman for Valeritas Holdings, Inc. (NASDAQ:VLRX), the maker of V-Go®, a daily insulin delivery device for people living with diabetes. Mr. Roberts holds a Bachelor of Science in Accounting and Finance from Boston College and is a Certified Public Accountant.

Richard Wooster

Richard Wooster is President of Research & Development at Tarveda and has three decades of experience in cancer genetics and pharmaceutical drug discovery and development. Previously, he was Vice President and Discovery Performance Unit Head in Oncology at GlaxoSmithKline. In this role, he led the evaluation of the metabolic pathways that are deregulated in cancer, led the PI3K portfolio of inhibitors in Oncology at GSK and was responsible for the clinical evaluation of the novel antimitotic kinase inhibitors to PLK and CENPE. Before this, Dr. Wooster led the translational medicine group in Oncology at GSK and worked on Tykerb®, Mekinist® and Tafinlar®. During his academic career, Dr. Wooster discovered the breast cancer susceptibility gene BRCA2, was one of the founders of the Cancer Genome Project at the Welcome Trust Sanger Institute where, among many achievements, mutations in BRAF were first discovered and he developed the COSMIC mutation database and website. He has more than 100 peer-reviewed articles and papers in scientific journals. Dr. Wooster has a First Class BSc in Biochemistry and a PhD in drug metabolizing enzymes, both from the University of Dundee, Scotland.

Mark Bilodeau

Mark Bilodeau is Executive Vice President, Drug Discovery at Tarveda, with more than 20 years of experience in medicinal chemistry and drug discovery. Previously, he was Senior Director of Medicinal Chemistry at Merck & Co. Inc., where he developed a broad background in drug discovery for the oncology, pain, neuroscience, ophthalmology, and cardiovascular therapeutic areas. While at Merck, Dr. Bilodeau was an inventor and team leader on seven molecules that advanced into clinical testing and also led a development team that brought one molecule from discovery through Phase I clinical testing. Dr. Bilodeau received a B.S. in Chemistry from Boston College and a Ph.D. in Organic Chemistry from Harvard University. He conducted postdoctoral studies at the Memorial Sloan-Kettering Cancer Center.

Sudha Kadiyala, PhD

Sudha Kadiyala is the Executive Vice President, Strategy & Development at Tarveda with 20 years of experience in the biotechnology industry. Previously, he worked at ATRM, a Johnson & Johnson company, with dual responsibilities as Senior Director of Product Development and Senior Director of Business Development & Strategic Planning.  During his 13 years at Johnson & Johnson, he served in various management roles in R&D and general management, including as Interim Head of Johnson & Johnson Regenerative Therapeutics, LLC.  Earlier in his career, Dr. Kadiyala held R&D management roles at Osiris Therapeutics, an adult stem cell company. He received a B. Technology from IIT, Bombay, a Masters of Engineering from Thayer School of Engineering at Dartmouth College and a PhD from the Johns Hopkins School of Medicine.